A Quick Look at Today's Ratings for Charles River(CRL.US), With a Forecast Between $155 to $180
Barclays Adjusts Price Target on Charles River Laboratories International to $155 From $145, Maintains Equalweight Rating
Jefferies Adjusts Price Target on Charles River Laboratories International to $142 From $100, Maintains Hold Rating
Citigroup Adjusts Price Target on Charles River Laboratories International to $150 From $175, Maintains Neutral Rating
Charles River Analyst Ratings
Baird Maintains Neutral on Charles River, Raises Price Target to $140
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $180 From $140, Maintains Buy Rating
Charles River Labs: Balancing Strong Q1 Performance With Market Uncertainties – Hold Rating Maintained
Research Alert: Crl: Q1 Results Top Expectations; 2025 Sales And Eps Guidance Raised
Baird Maintains Charles River(CRL.US) With Hold Rating, Raises Target Price to $118
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $105
BofA Securities Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $150
BofA Securities Cuts Charles River Laboratories International Price Target to $150 From $185
Baird Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $101
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $140 From $210
TD Cowen Maintains Charles River(CRL.US) With Hold Rating, Maintains Target Price $179
Charles River Labs Is Maintained at Equal-Weight by Barclays
Barclays Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $145
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $155
Mizuho Maintains Neutral on Charles River, Lowers Price Target to $155